By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProBioGen AG 

Goethestr. 54

Berlin    13086  Germany
Phone: 49-30-9-24-00-60 Fax: 49-30-924006-19



Company News
Merus (MRUS) Signs Commercial Multi-Product License For ProBioGen AG’s Glymaxx ADCC Enhancement Technology 6/1/2016 8:09:45 AM
ProBioGen AG Will License GlymaxX To Thermo Fisher Scientific (TMO) For Use In Developing Allergy Diagnostics 5/18/2016 9:22:14 AM
ProBioGen AG And EUCODIS Bioscience Sign Agreement To Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology 4/19/2016 11:05:12 AM
ProBioGen AG In Biosimilar Deal With Bio Farma Indonesia 10/28/2015 10:21:24 AM
Zymeworks Contracts ProBioGen AG For Bi-specific GlymaxX Antibody Cell Line Development 10/14/2015 11:19:31 AM
ProBioGen AG Inks Another Commercial Glymaxx License And Contract Manufacturing Service Agreement On Immuno-Oncology Antibody 10/1/2015 10:34:01 AM
Anti-Ebola MVA Vaccine Produced On ProBioGen AG’s Avian AGE1.CR Cell Line Platform In Clinical Trials 6/2/2015 11:30:55 AM
ProBioGen AG Hunts For Staff In €20 Million Investment 9/9/2014 10:02:05 AM
ProBioGen AG Signs GlymaxX ADCC Enhancement Technology License Deal 6/23/2014 1:59:59 PM
ProBioGen AG And Merus Sign Deal On GlymaxX® ADCC Enhancement Technology 3/4/2014 9:46:09 AM